Introduction
Over the past decade, epidemiologic studies have revealed a tremendous increase in the prevalence of diabetes and related mortality worldwide, especially in Asia. [1] [2] [3] The general population-based survey in China in 2010, using the American Diabetes Association 2010 criteria, revealed that the prevalence of diabetes and prediabetes in adults was 11.6% and 50.1%, respectively, indicating that China has the highest diabetes prevalence in Asia and largest absolute disease burden of diabetes in the world. 1 Lifestyle changes, aging, and obesity have become the main reasons for this increase in the prevalence of diabetes. 1, 4 Consequently, the economic burden is increasing accordingly. It was estimated that, in 2017, diabetes-related global healthcare expenditure was nearly US$850 billion for those aged 18 to 99 years, with the main reason for the high cost being the treatment of diabetes-related complications.
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In China, the economic expenditure caused by the diseases is greatly increased compared with decades ago, and is expected to rise in the future. 6, 7 In dealing with the prevention and treatment of diabetes, China has several challenges to face. First, in contrast with the high prevalence of diabetes, awareness of, adherence to treatment and control status among diabetic patients are relatively unsatisfactory, 1 with the serious imbalance in the ratio of physicians to patients making it difficult to achieve early diagnosis and management of diabetes and its related complications. Second, the existing hospital treatment system can barely meet the needs of the rapidly increasing diabetes population. Patients with diabetes and other metabolic diseases need comprehensive examination and evaluation of possible complications, but the process from testing to diagnosis and to treatment is time consuming. Third, the Healthy China 2030 strategy (http://www.who.int/ healthpromotion/conferences/9gchp/healthy-china/en/, accessed 10 September 2018), released in 2016 by the State of China to improve the overall health of its citizens, is currently in progress and being actively promoted, and the management of chronic diseases (including diabetes, hypertension, and dyslipidemia) should be handled at different levels within a tiered medical services policy. Because there are gaps between recommended guidelines and the real-world care for diabetes in China due to wide variations in the economy, cultural development, and medical service standards in different regions, it is necessary to first establish a pilot and standard system to deal with the challenges that can be replicated and extended to different regions nationwide, and to then dynamically integrate advanced technologies into this system. In order to meet all the challenges in the treatment of metabolic diseases, the National Metabolic Management Center (MMC) was founded in 2016. With advanced medical equipment and Internet of Things (IoT) technology, the MMC is committed to creating an online and offline integrated solution for diabetes, and for the entire spectrum of metabolic disease, to achieve a more convenient and precise model of care for patients. The MMC is focused on establishing highly efficient diagnosis and treatment, as well as comprehensive disease management both in and out of hospital.
One center, one stop, and one standard model in the MMC All MMCs in China have the same structure in terms of facilities, layout, and databases, as well as the same routine daily operations, aiming to establish a platform with standardized diagnosis and treatment of metabolic diseases and their long-term follow-up. This platform of treatment is called the "One Center, One Stop, and One Standard Model." In the MMCs, patients can enjoy one-stop care to receive a comprehensive series of services from registration, tests, evaluation, prescriptions, to health education. Under the guidance of the MMC Experts Committee, more than 400 stringent standard operating procedures are set up for quality control of the MMC operation. Furthermore, with technological innovations (e.g. the "all-in-one machine," which ingeniously integrates different examination equipment), the process of screening for complications can be greatly shortened. In addition, the MMC has established an independent digital medical record system integrating real-time in-and out-of-hospital information of patients into a centralized medical data center that can be exported through various IoT instruments, including apps, Wechat, and a teleconsultation system, to enable patient care to be extended from the MMC to anytime, anywhere outside the center.
Objective and long-term vision of the MMC
The objective of the MMC is to launch a new metabolic disease community management model based on the Internet health information platform. Moreover, the MMC helps improve adherence to and the effectiveness of treatment for patients, thus benefitting both patients and doctors. The proprietary electronic medical database in the MMC will make dynamic big-data analysis in diabetes epidemiology, prevention, diagnosis, and treatment very efficient and effective. Furthermore, this nationwide standardized care system also forms a collaborative research network for prospective interventional studies on treatment and prevention. Therefore, in the long run, the MMC will offer large amounts of data and evidence from hospital-based care to achieve long-term optimal health outcomes, enabling a replicable standard care model across the entire country that can form the base for future healthcare policy improvement.
Current progress
Currently, MMCs have been launched in approximately 100 hospitals and are providing care to more than 40 000 diabetic patients nationwide. By the end of this year, nearly 300 hospitals, including community hospitals, will be involved in the MMC network to truly enable a system of tiered medical services for diabetes management.
Recently, medical tools were developed to facilitate the screening, diagnosis, and treatment of diabetes in MMCs using artificial intelligence technology. One example is the Rui Ning Zhi Tang (瑞宁知糖), a diabetes risk assessment tool. The model of this assessment tool was constructed based on cohort follow-up data from the national large-scale epidemiological study, the Risk Evaluation of cAncers in Chinese diabetic Individuals: a lONgitudinal (REACTION) Study. 8 With this tool, people can be informed of their risk of developing diabetes in the next 3 years and obtain individualized recommendations, thus identifying subjects at high risk of diabetes and contributing to prevention and early diagnosis.
The second example is the Rui Ning Yu Tang (瑞宁预 糖), also called the "metabolic index," which predicts cardiovascular risk using six routine parameters. This was developed to assess the risk of diabetes-related cardiovascular complications within 3 years, and the model has been validated in large populations with favorable accuracy and reliability.
The third example is the Rui Ning Zhu Tang (瑞宁助 糖), the so called "Dia-Master" auxiliary system, which uses artificial intelligence to modify the diagnosis and treatment processes of diabetes by first standardizing and integrating desensitized patient information with the experience of the nation's top experts, then consolidating the latest international and domestic diabetesrelated guidelines and literature to construct a medical knowledge map, finally providing medical advice for patient care.
Conclusion
Today, we are facing great challenges and heavy workloads to control diabetes; hence, the set up of MMCs should be an endeavor to optimize diabetes management by establishing standardized care procedures across the entire country. This is one of the steps by which China can develop a comprehensive plan to conquer this disease and improve its long-term outcomes, as well as to lessen the huge economic burden associated with diabetes. The MMC is also a good example of chronic disease management through standardization of procedures and innovations in disease care by applying IoT technology in developing countries worldwide.
